Aligned Bio has developed a nanowire-based sensing platform designed to detect individual molecules with high sensitivity, with claims of read lengths of more than 1,000 bases using sequencing-by-synthesis reagents and up to 200x higher immunoassay sensitivity than conventional approaches. The technology originates from research at Lund University and Chalmers University of Technology and is designed for integration with industry-standard laboratory equipment and workflows. Founded in 2019 and headquartered in Lund, the company is transitioning from research to commercialization and plans to engage partners in the sequencing and proteomics industries. Recent financing of $3.6 million led by LMK will be used to scale nanowire consumable manufacturing and support commercial expansion. Pete Corish joined as CEO in June to lead commercialization efforts and partner discussions over the next six to twelve months. The company positions its platform as offering potential cost reductions and performance improvements for diagnostics, sequencing and proteomics applications.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2026